Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Amersham plc' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Amersham plc' found in 1 term [] and 2 definitions []
1 - 3 (of 3)     
Result Pages : [1]
MRI Resources 
PACS - Functional MRI - Collections - Equipment - Implant and Prosthesis pool - General
 
Amersham plcMRI Resource Directory:
 - Manufacturers -
 
www.amersham.com [This entry is marked for removal.]

GE Medical Systems and Amersham announced in April 2004 the completion of a share exchange acquisition of Amersham Health by GE. The result of this acquisition is the new GE Healthcare, based in the UK, totally owned by General Electric (GE).

Amersham plc, was a producer of contrast imaging agents used to enhance image quality in X-ray, magnetic resonance imaging, and ultrasound procedures. It was also a leading producer of radiopharmaceuticals used in nuclear medicine imaging. Amersham Health was the firm's imaging, diagnostics, and therapeutics segment. Amersham plc was involved in biotechnology research through its Amersham Biosciences unit, which made scanners, sequencers, microarrays, industrial separations, and other research supplies.
spacer
 
• Share the entry 'Amersham plc':  Facebook  Twitter  LinkedIn  

• View the NEWS results for 'Amersham plc' (3).Open this link in a new window.
 
Further Reading:
  News & More:
Recommended Share Exchange Acquisition by General Electric Company and GE Investments, Inc. of Amersham plc
Friday, 10 October 2003   by www.evaluatepharma.com    
MRI Resources 
Safety Products - Education - Spectroscopy - MR Myelography - Homepages - Patient Information
 
Amersham HealthMRI Resource Directory:
 - Manufacturers -
 
www.amershamhealth.com [This entry is marked for removal.]

GE Medical Systems and Amersham announced in April 2004 the completion of a share exchange acquisition of Amersham Health by GE. The result of this acquisition is the new GE Healthcare, based in the UK, totally owned by General Electric (GE).

Amersham Health, was the imaging diagnostics and therapy business of Amersham plc.

The rapid improvements in instrumentation, which have added benefit to the use of extracellular fluid agents such as Omniscan™, have also diminished the market potential for blood pool products such as Clariscan™. As a consequence, Amersham decided to discontinue the development of Clariscan™.
Contact Information
spacer

• View the DATABASE results for 'Amersham Health' (7).Open this link in a new window

 
Further Reading:
  News & More:
Recommended Share Exchange Acquisition by General Electric Company and GE Investments, Inc. of Amersham plc
Friday, 10 October 2003   by www.evaluatepharma.com    
GE Medical's new name: GE Healthcare
Friday, 6 February 2004   by milwaukee.bizjournals.com    
MRI Resources 
Movies - Quality Advice - Crystallography - Collections - Education pool - Non-English
 
Teslascan®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
(Mn-DPDP) This agent, mangafodipir trisodium, is a hepatocyte specific MRI contrast agent. Manganese is very toxic, so it has to be chelated and put in the form of a vitamin B6 analog, which is taken up by normal hepatocytes to some extent.
Teslascan® was developed in the early 1980's, went through clinical trials in the early 1990's, and was approved in 1997. One problem with assessing the efficacy of this agent is the fact that the phase III trials finished in the early 1990's, and the techniques used for MR today are very different from the techniques used almost a decade ago.
This contrast agent shortens the T1 relaxation time. On T1 weighted pictures it makes a normal liver look brighter. Since metastases, for example, do not generally take up this agent, the contrast between the enhancing liver and the non-enhancing lesions will increase on T1 weighted pictures. It does not have much effect on T2 weighted images.
Drug Information and Specification
NAME OF COMPOUND
Mangafodipir trisodium, Manganese dipyroxyl diphosphate, MN-DPDP
DEVELOPER
CENTRAL MOIETY
Mn2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
r1=2.3, r2=4.0, B0=1.0 T
PHARMACOKINETIC
Hepatobiliary, pancreatic, adrenal
290 mosm/kgH2O
CONCENTRATION
0.01 mmol/L
DOSAGE
5 µmol/kg, 0.5 ml/kg
PREPARATION
Finished product
INDICATION
Liver lesions
DEVELOPMENT STAGE
Approved
DISTRIBUTOR
See below
PRESENTATION
Vials of 100 ml
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA
Teslascan®
for sale
EU
Teslascan®
for sale
spacer

• View the DATABASE results for 'Teslascan®' (4).Open this link in a new window

 
Further Reading:
  Basics:
EMEA - Teslascan - SCIENTIFIC DISCUSSION(.pdf)
   by www.emea.europa.eu    
  News & More:
Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT.
2002
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
MRI Resources 
Education - Education pool - Pediatric and Fetal MRI - MRI Centers - Spine MRI - Libraries
 
     1 - 3 (of 3)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



Personalized protocols (age, gender, body habitus, etc.) lead to :
more automated planning 
improved patient comfort 
better diagnostics 
optimized image quality 
nothing 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 28 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]